Biotech Deals by the Numbers
Big pharma-biotech dealmaking continues to increase in popularity and price--companies with later-stage products are finding they truly can drive better deals. Meanwhile, drug companies are increasingly paying for their dealmaking with equity, as they leverage their balance sheet to offset research expenses.
You may also be interested in...
We revisit a chart from 1997 examining deal volume by clinical phase to highlight the changing landscape of late stage licensing.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.